NTLA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NTLA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Intellia Therapeutics's average Accounts Receivable for the three months ended in Jun. 2024 was $24.38 Mil. Intellia Therapeutics's Revenue for the three months ended in Jun. 2024 was $6.96 Mil. Hence, Intellia Therapeutics's Days Sales Outstanding for the three months ended in Jun. 2024 was 319.75.
The historical rank and industry rank for Intellia Therapeutics's Days Sales Outstanding or its related term are showing as below:
During the past 10 years, Intellia Therapeutics's highest Days Sales Outstanding was 202.37. The lowest was 20.31. And the median was 60.39.
Intellia Therapeutics's Days Sales Outstanding increased from Jun. 2023 (33.44) to Jun. 2024 (319.75).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
The historical data trend for Intellia Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intellia Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Days Sales Outstanding | Get a 7-Day Free Trial | 51.52 | 21.24 | 22.97 | 20.31 | 202.37 |
Intellia Therapeutics Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Days Sales Outstanding | Get a 7-Day Free Trial | 33.44 | 43.93 | - | 114.92 | 319.75 |
For the Biotechnology subindustry, Intellia Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Intellia Therapeutics's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Intellia Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as
Days Sales Outstanding (A: Dec. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2022 ) | + | Accounts Receivable (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) | * | Days in Period |
= | ( (3.768 | + | 36.456) | / | 2 ) | / | 36.275 | * | 365 |
= | 20.112 | / | 36.275 | * | 365 | ||||
= | 202.37 |
Intellia Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:
Days Sales Outstanding (Q: Jun. 2024 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Mar. 2024 ) | + | Accounts Receivable (A: Jun. 2024 )) | / | count ) | / | Revenue (A: Jun. 2024 ) | * | Days in Period |
= | ( (36.427 | + | 12.329) | / | 2 ) | / | 6.957 | * | 365 / 4 |
= | 24.378 | / | 6.957 | * | 365 / 4 | ||||
= | 319.75 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intellia Therapeutics (NAS:NTLA) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Intellia Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Eliana Clark | officer: EVP, Chief Technical Officer | C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139 |
Frank Verwiel | director | C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005 |
Laura Sepp-lorenzino | officer: EVP, Chief Scientific Officer | C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139 |
James Basta | officer: EVP, General Counsel | C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121 |
Derek Hicks | officer: EVP, Chief Business Officer | C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET SUITE 130, CAMBRIDGE MA 02139 |
David Lebwohl | officer: EVP, Chief Medical Officer | C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139 |
Glenn Goddard | officer: See Remarks | C/O INTELLIA THERAPEUTICS, INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139 |
John M. Leonard | director, officer: President and CEO | C/O INTELLIA THERAPEUTICS INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139 |
Muna Bhanji | director | C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
William J Chase | director | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
John F Crowley | director | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Georgia Keresty | director | C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730 |
Jean Francois Formela | director | C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451 |
Caroline Dorsa | director | BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Jose E Rivera | officer: EVP, General Counsel | C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139 |
From GuruFocus
By Marketwired • 04-29-2024
By Marketwired • 09-12-2024
By Marketwired • 05-09-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 06-25-2024
By Marketwired • 06-17-2024
By Marketwired • 05-02-2024
By Marketwired • 08-01-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.